Cargando…

Efficacy, Safety and Economic Evaluation of Wolbigachul-Tang for Chronic Cough Due to Upper Airway Cough Syndrome (UACS): A Study Protocol for Randomized, Double-Blind, Active-Comparator Controlled, Parallel, Exploratory Clinical Trial

Upper airway cough syndrome (UACS) is a common cause of chronic cough characterized by upper airway symptoms, including nasal discharge and throat discomfort. Empirical treatments for UASC-induced chronic cough, such as first-generation antihistamines, have been used; however, the long-term use of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Woo, Seong-Cheon, Lyu, Yee Ran, Lee, Su Won, Kwon, O-Jin, Choi, Young-Eun, Yang, Changsop, Park, Yang Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606134/
https://www.ncbi.nlm.nih.gov/pubmed/37893807
http://dx.doi.org/10.3390/healthcare11202733
_version_ 1785127243020763136
author Woo, Seong-Cheon
Lyu, Yee Ran
Lee, Su Won
Kwon, O-Jin
Choi, Young-Eun
Yang, Changsop
Park, Yang Chun
author_facet Woo, Seong-Cheon
Lyu, Yee Ran
Lee, Su Won
Kwon, O-Jin
Choi, Young-Eun
Yang, Changsop
Park, Yang Chun
author_sort Woo, Seong-Cheon
collection PubMed
description Upper airway cough syndrome (UACS) is a common cause of chronic cough characterized by upper airway symptoms, including nasal discharge and throat discomfort. Empirical treatments for UASC-induced chronic cough, such as first-generation antihistamines, have been used; however, the long-term use of these medicines has adverse effects. Therefore, we evaluate the efficacy, safety, and economic feasibility of Wolbigachul-tang (WBGCT), an herbal medication for UASC-induced chronic cough. This is a randomized, double-blind, active-comparator-controlled, parallel, and exploratory clinical trial. Thirty patients with UASC-induced chronic cough will be recruited and randomly allocated to the WBGCT and control groups in a 1:1 allocation ratio. The investigational medicine will be administered three times per day for 2 weeks (3 g of WBGCT at a time). The primary outcome measure is the cough symptom score measured at screening, before starting the trial, and after 2 and 4 weeks. Secondary outcome measures include the cough visual analog scale, nasal discharge score, questionnaire of clinical symptoms of cough and sputum, Leicester cough questionnaire-Korean version, integrative medicine outcome scale, integrative medicine patient satisfaction scale, and 5-level EuroQol 5-dimensional questionnaire, which will be assessed before starting the trial and after 2 and 4 weeks. This study aims to investigate the efficacy, safety, and economic feasibility of WBGCT in the treatment of chronic cough. Therefore, the results of this trial provide evidence for the application of WBGCT in the treatment of UACS-induced chronic cough.
format Online
Article
Text
id pubmed-10606134
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106061342023-10-28 Efficacy, Safety and Economic Evaluation of Wolbigachul-Tang for Chronic Cough Due to Upper Airway Cough Syndrome (UACS): A Study Protocol for Randomized, Double-Blind, Active-Comparator Controlled, Parallel, Exploratory Clinical Trial Woo, Seong-Cheon Lyu, Yee Ran Lee, Su Won Kwon, O-Jin Choi, Young-Eun Yang, Changsop Park, Yang Chun Healthcare (Basel) Study Protocol Upper airway cough syndrome (UACS) is a common cause of chronic cough characterized by upper airway symptoms, including nasal discharge and throat discomfort. Empirical treatments for UASC-induced chronic cough, such as first-generation antihistamines, have been used; however, the long-term use of these medicines has adverse effects. Therefore, we evaluate the efficacy, safety, and economic feasibility of Wolbigachul-tang (WBGCT), an herbal medication for UASC-induced chronic cough. This is a randomized, double-blind, active-comparator-controlled, parallel, and exploratory clinical trial. Thirty patients with UASC-induced chronic cough will be recruited and randomly allocated to the WBGCT and control groups in a 1:1 allocation ratio. The investigational medicine will be administered three times per day for 2 weeks (3 g of WBGCT at a time). The primary outcome measure is the cough symptom score measured at screening, before starting the trial, and after 2 and 4 weeks. Secondary outcome measures include the cough visual analog scale, nasal discharge score, questionnaire of clinical symptoms of cough and sputum, Leicester cough questionnaire-Korean version, integrative medicine outcome scale, integrative medicine patient satisfaction scale, and 5-level EuroQol 5-dimensional questionnaire, which will be assessed before starting the trial and after 2 and 4 weeks. This study aims to investigate the efficacy, safety, and economic feasibility of WBGCT in the treatment of chronic cough. Therefore, the results of this trial provide evidence for the application of WBGCT in the treatment of UACS-induced chronic cough. MDPI 2023-10-13 /pmc/articles/PMC10606134/ /pubmed/37893807 http://dx.doi.org/10.3390/healthcare11202733 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Study Protocol
Woo, Seong-Cheon
Lyu, Yee Ran
Lee, Su Won
Kwon, O-Jin
Choi, Young-Eun
Yang, Changsop
Park, Yang Chun
Efficacy, Safety and Economic Evaluation of Wolbigachul-Tang for Chronic Cough Due to Upper Airway Cough Syndrome (UACS): A Study Protocol for Randomized, Double-Blind, Active-Comparator Controlled, Parallel, Exploratory Clinical Trial
title Efficacy, Safety and Economic Evaluation of Wolbigachul-Tang for Chronic Cough Due to Upper Airway Cough Syndrome (UACS): A Study Protocol for Randomized, Double-Blind, Active-Comparator Controlled, Parallel, Exploratory Clinical Trial
title_full Efficacy, Safety and Economic Evaluation of Wolbigachul-Tang for Chronic Cough Due to Upper Airway Cough Syndrome (UACS): A Study Protocol for Randomized, Double-Blind, Active-Comparator Controlled, Parallel, Exploratory Clinical Trial
title_fullStr Efficacy, Safety and Economic Evaluation of Wolbigachul-Tang for Chronic Cough Due to Upper Airway Cough Syndrome (UACS): A Study Protocol for Randomized, Double-Blind, Active-Comparator Controlled, Parallel, Exploratory Clinical Trial
title_full_unstemmed Efficacy, Safety and Economic Evaluation of Wolbigachul-Tang for Chronic Cough Due to Upper Airway Cough Syndrome (UACS): A Study Protocol for Randomized, Double-Blind, Active-Comparator Controlled, Parallel, Exploratory Clinical Trial
title_short Efficacy, Safety and Economic Evaluation of Wolbigachul-Tang for Chronic Cough Due to Upper Airway Cough Syndrome (UACS): A Study Protocol for Randomized, Double-Blind, Active-Comparator Controlled, Parallel, Exploratory Clinical Trial
title_sort efficacy, safety and economic evaluation of wolbigachul-tang for chronic cough due to upper airway cough syndrome (uacs): a study protocol for randomized, double-blind, active-comparator controlled, parallel, exploratory clinical trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606134/
https://www.ncbi.nlm.nih.gov/pubmed/37893807
http://dx.doi.org/10.3390/healthcare11202733
work_keys_str_mv AT wooseongcheon efficacysafetyandeconomicevaluationofwolbigachultangforchroniccoughduetoupperairwaycoughsyndromeuacsastudyprotocolforrandomizeddoubleblindactivecomparatorcontrolledparallelexploratoryclinicaltrial
AT lyuyeeran efficacysafetyandeconomicevaluationofwolbigachultangforchroniccoughduetoupperairwaycoughsyndromeuacsastudyprotocolforrandomizeddoubleblindactivecomparatorcontrolledparallelexploratoryclinicaltrial
AT leesuwon efficacysafetyandeconomicevaluationofwolbigachultangforchroniccoughduetoupperairwaycoughsyndromeuacsastudyprotocolforrandomizeddoubleblindactivecomparatorcontrolledparallelexploratoryclinicaltrial
AT kwonojin efficacysafetyandeconomicevaluationofwolbigachultangforchroniccoughduetoupperairwaycoughsyndromeuacsastudyprotocolforrandomizeddoubleblindactivecomparatorcontrolledparallelexploratoryclinicaltrial
AT choiyoungeun efficacysafetyandeconomicevaluationofwolbigachultangforchroniccoughduetoupperairwaycoughsyndromeuacsastudyprotocolforrandomizeddoubleblindactivecomparatorcontrolledparallelexploratoryclinicaltrial
AT yangchangsop efficacysafetyandeconomicevaluationofwolbigachultangforchroniccoughduetoupperairwaycoughsyndromeuacsastudyprotocolforrandomizeddoubleblindactivecomparatorcontrolledparallelexploratoryclinicaltrial
AT parkyangchun efficacysafetyandeconomicevaluationofwolbigachultangforchroniccoughduetoupperairwaycoughsyndromeuacsastudyprotocolforrandomizeddoubleblindactivecomparatorcontrolledparallelexploratoryclinicaltrial